---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-171310"
form_type: "8-K"
ticker: null
cik: "0001840574"
company_name: "Verve Therapeutics, Inc."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:46:09.184084+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Verve Therapeutics appoints Jodie Morrison and Vertex exec Nia Tatsis to board

## Summary
- Board expanded to nine members; Morrison (Class I, term to 2025) and Tatsis (Class III, term to 2027) elected June 26, 2024.
- Morrison is independent; Tatsis is an executive officer of Vertex, Verve's collaborator under a 2022 strategic deal.
- Each new director received an option for 267,541 shares at $5.02 per share, vesting over three years.
- Tatsis's appointment deepens ties with Vertex, which paid Verve $25M upfront and up to $406M in milestones and royalties.

## SEC filing metadata
- accession: 0001193125-24-171310
- form_type: 8-K
- cik: 0001840574
- company_name: Verve Therapeutics, Inc.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/0001193125-24-171310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/d821295d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-171310
- JSON: https://secwatch.observer/filing/0001193125-24-171310.json
- Plain text: https://secwatch.observer/filing/0001193125-24-171310.txt

## Key facts
- Executive change
  Jodie Morrison was elected as Director at Verve Therapeutics, Inc..
  - Action: elected
  - Role: Director
  source text: elected, effective immediately, Jodie Morrison as a member of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/0001193125-24-171310-index.htm
- Executive change
  Ourania "Nia" Tatsis, Ph.D. was elected as Director at Verve Therapeutics, Inc..
  - Action: elected
  - Role: Director
  source text: Ourania "Nia" Tatsis, Ph.D. as a member of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840574/000119312524171310/0001193125-24-171310-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.